Racura Oncology Ltd (FRA:FN3)

Market Cap	195.19M -48.1%
Revenue (ttm)	1.70M -46.5%
Net Income	-6.71M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.9300
Previous Close	0.9300
Day's Range	0.9300 - 0.9300
52-Week Range	0.9200 - 2.1800
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Racura Oncology

Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FN3

Financial Performance

In fiscal year 2026, Racura Oncology's revenue was 2.81 million, a decrease of -46.50% compared to the previous year's 5.25 million. Losses were -11.09 million, 131.6% more than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error